Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palmitoylethanolamide - Prismic Pharmaceuticals

Drug Profile

Palmitoylethanolamide - Prismic Pharmaceuticals

Alternative Names: FSD 201; FSD 201 micro-PEA; FSD-PEA; micro PEA plus pregabalin; micro-palmitoylethanolamide; micro-palmitoylethanolamide (micro-PEA) plus pregabalin; micro-PEA; PP 101; PP 101 micro-PEA; Ultra Micro-Palmitolylethanolamide; ultra-micro PEA; ultra-micronized palmitoyl ethylamine; ultra-micronized PEA

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epitech Group
  • Developer Prismic Pharmaceuticals
  • Class Amides; Analgesics; Anti-inflammatories; Antivirals; Cannabinoids; Ethanolamines; Irritable bowel syndrome therapies; Neuroprotectants; Palmitic acids
  • Mechanism of Action Cannabinoid receptor agonists; G-protein-coupled receptor 55 modulators; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Musculoskeletal pain
  • No development reported Inflammation; Irritable bowel syndrome; Neurological disorders; Pain
  • Discontinued COVID 2019 infections

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA
  • 05 Jul 2023 FSD Pharma terminates a phase II trials in Musculoskeletal pain in USA and Canada for business reasons and not for reasons related to safety or efficacy (PO) (NCT05652907)
  • 28 May 2023 No recent reports of development identified for preclinical development in Neurological-disorders in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top